EXFY vs. DAVA, WEAV, DOMO, OSPN, DH, ECX, LZMH, CANG, CCSI, and BLZE
Should you be buying Expensify stock or one of its competitors? The main competitors of Expensify include Endava (DAVA), Weave Communications (WEAV), Domo (DOMO), Onespan (OSPN), Definitive Healthcare (DH), ECARX (ECX), LZ Technology (LZMH), Cango (CANG), Consensus Cloud Solutions (CCSI), and Backblaze (BLZE). These companies are all part of the "computer software" industry.
Expensify vs. Its Competitors
Endava (NYSE:DAVA) and Expensify (NASDAQ:EXFY) are both small-cap computer software companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, profitability, institutional ownership, earnings, valuation, media sentiment, dividends and analyst recommendations.
62.2% of Endava shares are owned by institutional investors. Comparatively, 68.4% of Expensify shares are owned by institutional investors. 18.8% of Endava shares are owned by insiders. Comparatively, 17.3% of Expensify shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Endava has a beta of 1.13, meaning that its share price is 13% more volatile than the S&P 500. Comparatively, Expensify has a beta of 1.72, meaning that its share price is 72% more volatile than the S&P 500.
Endava has higher revenue and earnings than Expensify. Expensify is trading at a lower price-to-earnings ratio than Endava, indicating that it is currently the more affordable of the two stocks.
Endava has a net margin of 2.73% compared to Expensify's net margin of -10.72%. Endava's return on equity of 5.56% beat Expensify's return on equity.
In the previous week, Expensify had 1 more articles in the media than Endava. MarketBeat recorded 3 mentions for Expensify and 2 mentions for Endava. Expensify's average media sentiment score of 1.87 beat Endava's score of 0.47 indicating that Expensify is being referred to more favorably in the news media.
Endava currently has a consensus target price of $20.78, suggesting a potential upside of 116.35%. Expensify has a consensus target price of $4.00, suggesting a potential upside of 108.88%. Given Endava's higher possible upside, equities analysts clearly believe Endava is more favorable than Expensify.
Summary
Endava beats Expensify on 10 of the 16 factors compared between the two stocks.
Get Expensify News Delivered to You Automatically
Sign up to receive the latest news and ratings for EXFY and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding EXFY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Expensify Competitors List
Related Companies and Tools
This page (NASDAQ:EXFY) was last updated on 9/16/2025 by MarketBeat.com Staff